Calendario de promoción FSD Pharma Inc.
Horario avanzado
gráfico sencillo
Acerca de la empresa FSD Pharma Inc.
FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.IPO date | 2018-06-08 |
---|---|
ISIN | CA35954B2066 |
Industry | IT Services |
Sector | Information Technology |
Валюта | usd |
Валюта отчета | usd |
Сайт | https://www.fsdpharma.com |
Цена ао | 0.701 |
Cambio de precio por día: | 0% (5.39) |
---|---|
Cambio de precio por semana.: | 0% (5.39) |
Cambio de precio por mes: | 0% (5.39) |
Cambio de precio en 3 meses.: | +40% (3.85) |
Cambio de precio en seis meses: | -43.59% (9.555) |
Cambio de precio por año: | +485.87% (0.92) |
Cambio de precio en 3 años.: | +428.43% (1.02) |
Cambio de precio en 5 años.: | +4.46% (5.16) |
Cambio de precio en 10 años.: | 0% (5.39) |
Cambio de precio desde principios de año.: | 0% (5.39) |
|
Subestimación
|
Eficiencia
|
|||||||||||||||||||||||||||||||||||||
Dividendos
|
Deber
|
Impulso de crecimiento
|
Instituciones | Volumen | Compartir, % |
---|---|---|
AdvisorShares Investments, LLC | 270316 | 0.67 |
Renaissance Technologies, LLC | 69200 | 0.17 |
Scotia Capital Inc. | 61273 | 0.15 |
UBS Group AG | 26362 | 0.07 |
Group One Trading, L.P. | 17653 | 0.04 |
TWO SIGMA SECURITIES, LLC | 13584 | 0.03 |
Susquehanna International Group, LLP | 11791 | 0.03 |
Td Waterhouse Canada Inc. | 10373 | 0.03 |
Citadel Advisors Llc | 2483 | 0.01 |
Royal Bank of Canada | 2450 | 0.01 |
ETF | Compartir, % | Rentabilidad del año, % | Dividendos, % |
---|---|---|---|
SPDR Portfolio Emerging Markets ETF | 0.00339 | 11.59 | 3.1879 |
Dimensional Emerging Markets Core Equity 2 ETF | 0.00291 | 15.96 | 3.34087 |
SPDR Portfolio Europe ETF | 0.00138 | 8.94 | 3.66537 |
Supervisor | Título profesional | Pago | año de nacimiento |
---|---|---|---|
Mr. Zeeshan Saeed | Founder, CEO, President & Executive Co-Chairman | 222.62k | 1970 (55 años) |
Mr. Anthony John Durkacz | Founder & Executive Co-Chairman | 222.62k | 1976 (49 años) |
Mr. Nathan Coyle CPA | Chief Financial Officer | 178.21k | 1981 (44 año) |
Mr. Donal Carroll CPA | Chief Operating Officer | 225.62k | 1977 (48 años) |
Dr. Lakshmi P. Kotra BPHARM, Ph.D. | CEO of Lucid & Director | 144.72k | 1971 (54 año) |
Dr. Andrzej Chruscinski M.D., Ph.D. | Vice President of Clinical & Scientific Affairs of Lucid | 110.3k | |
Mr. Kevin Cassidy | Vice President of Quality-Lucid | 144.82k | |
Ms. Maryann Adesso | Corporate Secretary | N/A | |
Randell Mack | President of FSD BioSciences | N/A |
DIRECCIÓN: Canada, Toronto. ON ML A, 199 Bay Street - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://www.fsdpharma.com
Sitio web: https://www.fsdpharma.com